The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma

被引:25
作者
Makino, Y [1 ]
Yamanoi, A [1 ]
Kimoto, T [1 ]
El-Assal, ON [1 ]
Kohno, H [1 ]
Nagasue, N [1 ]
机构
[1] Shimane Med Univ, Dept Surg 2, Izumo, Shimane 6938501, Japan
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: This study retrospectively evaluated the association between perioperative blood transfusion and intrahepatic recurrence in patients with hepatocellular carcinoma (HCC) who had undergone curative hepatic resections. METHODS: Hepatic resection was performed with curative intent in 195 patients with primary HCC between 1985 and 1996; Patients who had received perioperative blood transfusion (transfused group: n = 117) and those who had no perioperative blood transfusion (nontransfused group: n = 78) were compared in terms of conventional prognostic variables and cancer-free survival by the univariate and multivariate analyses. RESULTS: The 1-, 3-, and 5-yr cancer-free survival rates in the nontransfused and transfused groups were 83.4% and 67.9%. 33.0% and 36.7%, and 23.1% and 24.6%, respectively (p = 0.175). Multivariate analysis of prognostic factors in all patients revealed that vascular invasion, tumor size (greater than or equal to 5 cm), and Child's class were independent factors for intrahepatic recurrence. Further analyses in various stratified groups showed that perioperative blood transfusion was an independent predictor of prognosis in HCC patients with portal vein invasion (RR: 2.8, p = 0.0038). The 1-, 3-, and 5-yr survival rates in the nontransfused and transfused groups with portal vein invasion were 71.9% and 41.6%, 54.5% and 10.9%, and 26% and 0%, respectively (p = 0.0003). CONCLUSIONS: We conclude that perioperative blood transfusions enhance the risk of intrahepatic recurrence of HCC in patients with portal vein invasion. As well, the more difficult surgery and the increased manipulation of the liver that occur in these cases create a greater possibility of tumor dissemination. (C) 2000 by Am. Cell. of Gastroenterology.
引用
收藏
页码:1294 / 1300
页数:7
相关论文
共 46 条
[1]   T-CELL IMMUNE-RESPONSES TO CANCER - A NEW LOOK [J].
BODMER, W .
HUMAN IMMUNOLOGY, 1991, 30 (04) :259-261
[2]  
Brittenden J, 1996, CANCER-AM CANCER SOC, V77, P1226, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO
[3]  
2-G
[4]  
BURROWS L, 1982, LANCET, V2, P662
[5]   BLOOD-TRANSFUSIONS AND PROGNOSIS IN COLORECTAL-CANCER [J].
BUSCH, ORC ;
HOP, WCJ ;
VANPAPENDRECHT, MAWH ;
MARQUET, RL ;
JEEKEL, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (19) :1372-1376
[6]  
CHESI R, 1989, CANCER, V64, P1727, DOI 10.1002/1097-0142(19891015)64:8<1727::AID-CNCR2820640829>3.0.CO
[7]  
2-Y
[8]  
CHOI JH, 1995, ONCOLOGY, V52, P170
[9]   PERIOPERATIVE BLOOD-TRANSFUSIONS DO NOT AFFECT DISEASE RECURRENCE OF PATIENTS UNDERGOING CURATIVE RESECTION OF COLORECTAL-CARCINOMA - A MAYO/NORTH CENTRAL CANCER-TREATMENT GROUP-STUDY [J].
DONOHUE, JH ;
WILLIAMS, S ;
CHA, S ;
WINDSCHITL, HE ;
WITZIG, TE ;
NELSON, H ;
FITZGIBBONS, RJ ;
WIEAND, HS ;
MOERTEL, CG .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1671-1678
[10]   Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer [J].
Edna, TH ;
Bjerkeset, T .
DISEASES OF THE COLON & RECTUM, 1998, 41 (04) :451-459